Actelion issues invitation to 2016 Annual General Meeting of Shareholders
GlobeNewswire
ALLSCHWIL/BASEL, SWITZERLAND - 6 April 2016- Actelion Ltd (ATLN.VX) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of the year ending 31 December 2015 will be held on 4 May 2016 at 10.00 CEST at the Congress Center, Messe Basel, Switzerland.
At this year`s meeting the Board of Directors is proposing a dividend payment of CHF 1.50 per share, an increase of 15%. The Board is also proposing the reduction of share capital by cancelation of shares repurchased on a second trading line as part of the company`s share repurchase program of up to 10 million shares, initiated on 9 April 2015. Also, the Board is proposing the approval of a maximum compensation for the non-executive members of the Board of Directors and the maximum compensation amount for the Actelion Executive Committee.
NOTES TO SHAREHOLDERS The invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) on 6 April 2016 and is available, together with the Company`s Annual Report and Compensation Report, on www.actelion.com/agm.
In order to attend and vote at the Annual General Meeting of Shareholders, Shareholders must have been registered in the Company`s shareholder register by 22 April 2016 at the latest.
###
NOTES TO EDITORS
AGENDA FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2016 1. Annual Report 2015, Consolidated Financial Statements 2015, Statutory Financial Statements 2015 and Compensation Report 2015 1.1. Approval of Annual Report 2015, Consolidated Financial Statements 2015 and Statutory Financial Statements 2015 1.2. Consultative Vote on the Compensation Report 2015 2. Appropriation of Available Earnings and Distribution against reserve from capital contribution 3. Discharge of the Board of Directors and of the Executive Management 4. Reduction of Share Capital by Cancelation of Repurchased Shares 5. Extension of Existing Authorized Capital 6. Board Elections 6.1. Re-election of the Board of Directors 6.2. Re-election of the Chairperson of the Board of Directors 6.3. Re-election of the Compensation Committee 7. Approval of Board Compensation and Executive Management Compensation 7.1. Approval of Board Compensation (Non-Executive Directors) 7.2. Approval of Executive Management Compensation 2017 (Maximum Amount) 8. Election of Independent Proxy 9. Election of the Statutory Auditors
Actelion Ltd. Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.
For further information please contact: Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 www.actelion.com
The above information contains certain "forward-looking statements", relating to the company`s business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company`s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company`s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Actelion Pharmaceuticals Ltd via GlobeNewswire HUG#2000832
